The European Society of Cardiology (ESC) Congress 2024 addressed critical issues in cardiovascular care, including inclusivity in clinical trials and the impact of GLP-1 therapies. Discussions emphasized the importance of diversity in patient populations and the potential benefits and challenges associated with emerging treatments.
Enhancing Inclusivity in Clinical Trials
Dr. Dipti Itchhaporia, chair of the Health Equity Task Force and past president of the American College of Cardiology (ACC), highlighted the progress being made in clinical research to ensure inclusivity. "There's a recognition that we do need diversity in the patient population if we're going to serve these patients," she noted. The use of digital tools, such as smartphones and telehealth, is facilitating patient enrollment and overcoming traditional barriers. Dr. Itchhaporia pointed out that data derived from one demographic group may not be applicable to others, underscoring the necessity for diverse representation in trials.
GLP-1 Therapies and Cardiovascular Benefits
The emergence of GLP-1 therapies has significantly impacted the treatment landscape for cardiologists. These therapies have demonstrated cardiovascular benefits in diabetic patients and aid in weight loss for obese patients, which translates to improved cardiovascular outcomes. "We know that, in general, cardiovascular disease is increasing because of the risk factors, and 2 common risk factors are obesity and diabetes. So if we can target those patients, then we can say that we're going to help in terms of their cardiovascular outcomes," Dr. Itchhaporia explained.
Health Equity Concerns
Despite the benefits, the high cost of GLP-1 drugs and supply limitations raise significant health equity concerns. Dr. Itchhaporia noted that the increased utilization of these drugs for obese patients has reduced access for diabetic patients. "There's equity issues on both sides there, right? Because I think both sets need it. The question is, can they get it because of the supply, and can they afford to get it? So I think that's a health equity issue."
These challenges highlight the need for strategies to ensure equitable access to these potentially life-saving therapies.
